Neurocrine Biosciences, Inc. (Nasdaq: NBIX) 47% HIGHER; today announced statistically significant and clinically meaningful top-line efficacy results from its Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE